Completed PHASE2 INTERVENTIONAL 1-arm NCT00268840

The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer

National Trial Phase II to Study the Combination of Gemcitabine and Docetaxel in Patients With Locally Advanced or Metastatic Pancreatic or Biliary Adenocarcinoma That Cannot be Removed by Surgery

Sponsor: ARCAGY/ GINECO GROUP

Conditions Biliary Tract Neoplasms Pancreatic Neoplasms

Interventions Docetaxel Gemcitabine

Updated 5 times since 2017 Last updated: Jun 29, 2011 Started: Aug 31, 2001 Primary completion: Feb 28, 2006 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Biliary Tract Neoplasms and Pancreatic Neoplasms, this trial is completed. The trial is conducted by ARCAGY/ GINECO GROUP and has accumulated 5 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ARCAGY/ GINECO GROUP

Data source: ARCAGY/ GINECO GROUP

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France